TY - JOUR
T1 - Sleep extension and metabolic health in male overweight/obese short sleepers
T2 - A randomised controlled trial
AU - Hartescu, Iuliana
AU - Stensel, David J.
AU - Thackray, Alice E.
AU - King, James A.
AU - Dorling, James L.
AU - Rogers, Eva N.
AU - Hall, Andrew P.
AU - Brady, Emer M.
AU - Davies, Melanie J
AU - Yates, Thomas
AU - Morgan, Kevin
N1 - Funding Information:
The trial was funded by Loughborough University and the NIHR Leicester Biomedical Research Centre.
Funding Information:
The trial was funded by Loughborough University and the NIHR Leicester Biomedical Research Centre. This research was supported by the NIHR Leicester Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Publisher Copyright:
© 2021 European Sleep Research Society
PY - 2022/4
Y1 - 2022/4
N2 - While limited evidence suggests that longer sleep durations can improve metabolic health in habitual short sleepers, there is no consensus on how sustained sleep extension can be achieved. A total of 18 men (mean [SD] age 41 [9] years), who were overweight/obese (mean [SD] body mass index 30 [3] kg/m2) and short sleepers at increased risk of type 2 diabetes were randomised to a 6-week sleep-extension programme based on cognitive behavioural principles (n = 10) or a control (n = 8) group. The primary outcome was 6-week change in actigraphic total sleep time (TST). Fasting plasma insulin, insulin resistance (Homeostatic Model Assessment for Insulin Resistance [HOMA-IR]), blood pressure, appetite-related hormones from a mixed-meal tolerance test, and continuous glucose levels were also measured. Baseline to 6-week change in TST was greater in the sleep-extension group, at 79 (95% confidence interval [CI] 68.90, 88.05) versus 6 (95% CI −4.43, 16.99) min. Change in the sleep-extension and control groups respectively also showed: lower fasting insulin (−11.03 [95% CI −22.70, 0.65] versus 7.07 [95% CI −4.60, 18.74] pmol/L); lower systolic (−11.09 [95% CI −17.49, −4.69] versus 0.76 [95% CI −5.64, 7.15] mmHg) and diastolic blood pressure (−12.16 [95% CI −17.74, −6.59] versus 1.38 [95% CI −4.19, 6.96] mmHg); lower mean amplitude of glucose excursions (0.34 [95% CI −0.57, −0.12] versus 0.05 [95% CI −0.20, 0.30] mmol/L); lower fasting peptide YY levels (−18.25 [95%CI −41.90, 5.41] versus 21.88 [95% CI −1.78, 45.53] pg/ml), and improved HOMA-IR (−0.51 [95% CI −0.98, −0.03] versus 0.28 [95% CI −0.20, 0.76]). Our protocol increased TST and improved markers of metabolic health in male overweight/obese short sleepers.
AB - While limited evidence suggests that longer sleep durations can improve metabolic health in habitual short sleepers, there is no consensus on how sustained sleep extension can be achieved. A total of 18 men (mean [SD] age 41 [9] years), who were overweight/obese (mean [SD] body mass index 30 [3] kg/m2) and short sleepers at increased risk of type 2 diabetes were randomised to a 6-week sleep-extension programme based on cognitive behavioural principles (n = 10) or a control (n = 8) group. The primary outcome was 6-week change in actigraphic total sleep time (TST). Fasting plasma insulin, insulin resistance (Homeostatic Model Assessment for Insulin Resistance [HOMA-IR]), blood pressure, appetite-related hormones from a mixed-meal tolerance test, and continuous glucose levels were also measured. Baseline to 6-week change in TST was greater in the sleep-extension group, at 79 (95% confidence interval [CI] 68.90, 88.05) versus 6 (95% CI −4.43, 16.99) min. Change in the sleep-extension and control groups respectively also showed: lower fasting insulin (−11.03 [95% CI −22.70, 0.65] versus 7.07 [95% CI −4.60, 18.74] pmol/L); lower systolic (−11.09 [95% CI −17.49, −4.69] versus 0.76 [95% CI −5.64, 7.15] mmHg) and diastolic blood pressure (−12.16 [95% CI −17.74, −6.59] versus 1.38 [95% CI −4.19, 6.96] mmHg); lower mean amplitude of glucose excursions (0.34 [95% CI −0.57, −0.12] versus 0.05 [95% CI −0.20, 0.30] mmol/L); lower fasting peptide YY levels (−18.25 [95%CI −41.90, 5.41] versus 21.88 [95% CI −1.78, 45.53] pg/ml), and improved HOMA-IR (−0.51 [95% CI −0.98, −0.03] versus 0.28 [95% CI −0.20, 0.76]). Our protocol increased TST and improved markers of metabolic health in male overweight/obese short sleepers.
KW - cardiovascular health
KW - insufficient sleep
KW - metabolic health
KW - short sleep duration
UR - http://www.scopus.com/inward/record.url?scp=85113731974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113731974&partnerID=8YFLogxK
U2 - 10.1111/jsr.13469
DO - 10.1111/jsr.13469
M3 - Article
C2 - 34459060
AN - SCOPUS:85113731974
VL - 31
JO - Journal of Sleep Research
JF - Journal of Sleep Research
SN - 0962-1105
IS - 2
M1 - e13469
ER -
